Shares of uniQure N.V. (QURE) were trading up +2.50 or +16.77 percent to $17.41 per share in Thursday's premarket after the company announced positive preliminary results in a Phase I/ II clinical trial that assessed the company's gene therapy in patients with hemophilia B. uniQure stock closed at $14.91, down -1.26 or -7.79 percent in ... READ MORE Read the rest of UniQure (QURE) Shares Rally on Positive Results in Gene Therapy Trials at InvestorGuide.com .